Novartis has handed back its brain-shuttle deal, and BioArctic says it has signed five collaboration agreements on the same technology to date. On the evening of 2 November the Swedish company said Novartis had terminated the option, collaboration and licence agreement the two signed in August 2025.
What the deal was
The partnership set out to combine BioArctic's BrainTransporter platform, which uses the transferrin receptor to carry drugs across the blood-brain barrier, with an undisclosed Novartis antibody. BioSpace reports the target was a neurodegenerative condition and that the deal could have been worth more than $772 million, with a $30 million cash payment up front.
What happens now
BioArctic keeps the full $30 million upfront and will book the remaining unrecognised portion as revenue in 2026. It describes the move as Novartis discontinuing its own programme, and says the decision has nothing to do with the BrainTransporter technology. The release has no executive comment.
Novartis told BioSpace by email that the call followed a review of its early research priorities and is "unrelated to safety or efficacy concerns". It added that it remains committed to getting therapeutics across the blood-brain barrier.
Where Novartis is putting its brain-delivery bets
Novartis has another horse in this race. In July 2025 it took an option on Sironax's Brain Delivery Module platform, worth up to $175 million in upfront and near-term payments, and BioSpace reports it exercised that option to take global rights in September 2026.
BioArctic's other partners
The BrainTransporter platform still has company. BioArctic has collaborations with Eisai, Bristol Myers Squibb and Eli Lilly, according to BioSpace. Lilly paid $30 million upfront in June in a deal worth up to $770 million.
The bigger picture
Getting large molecules into the brain is one of the most contested technology plays in CNS. Big pharma is collecting shuttle platforms, and with several on the table it's no surprise that some partnerships get pruned as programmes are ranked against each other. For platform companies, a termination with the cash kept and other partners in place is a manageable setback. The real test is which shuttle produces the first clinical data that changes how a CNS antibody performs.
What it means for hiring
- Brain-delivery platforms are a crowded BD market. Companies like BioArctic need business development leaders who can sell a technology to several pharma partners at once and replace lost deals quickly.
- Large pharma reshaping early neuroscience portfolios can bring experienced discovery and translational CNS scientists to market. Mid-sized neuroscience developers should keep an eye out.
- Shuttle-enabled antibodies blend biologics engineering with neurology clinical development, a hybrid skill set we expect to stay in short supply.
Building a team in Therapeutics?
Harry Aaronson specialises in Therapeutics hiring at QP Group. Talk to Harry about the market, salaries or a search.
Sources
- BioArctic collaborator Novartis terminates agreement · BioArctic via PR Newswire · 2 Nov 2026
- Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance · BioSpace · 3 Nov 2026
Written by QP Group from the reporting and announcements above. Figures and quotes belong to the original sources.
More from Tx Weekly
- AbbVie pays $100M upfront for the IBD drug Nxera shelved a year ago8 Nov 2026
- Sanofi pulls the plug on Nurix's oral STAT6 degrader three months into Phase 18 Nov 2026
- Teva's CNS brands grow 33% while its total revenue slips 2%8 Nov 2026
- J&J's oral IL-23 pill Icotyde hits its Phase 3 goal in psoriatic arthritis8 Nov 2026